scholarly journals Intake of polyphenol-rich pomegranate pure juice influences urinary glucocorticoids, blood pressure and homeostasis model assessment of insulin resistance in human volunteers

2012 ◽  
Vol 1 ◽  
Author(s):  
Catherine Tsang ◽  
Nacer F. Smail ◽  
S. Almoosawi ◽  
I. Davidson ◽  
Emad A. S. Al-Dujaili
Keyword(s):  
Insulin Resistance ◽  
Blood Pressure ◽  
Pulse Wave Velocity ◽  
Wave Velocity ◽  
Pulse Wave ◽  
Similar Amount ◽  
Model Assessment ◽  
Homeostasis Model Assessment ◽  
The Metabolic Syndrome ◽  
Therapeutic Benefits

AbstractPomegranate juice (PJ; also known as pomegreat pure juice) provides a rich and varied source of polyphenolic compounds that may offer cardioprotective, anti-atherogenic and antihypertensive effects. The aim of this study was to investigate the effect of PJ consumption on glucocorticoids levels, blood pressure (BP) and insulin resistance in volunteers at high CVD risk. Subjects (twelve males and sixteen females) participated in a randomised, placebo-controlled cross-over study (BMI: 26·77 (sd 3·36) kg/m2; mean age: 50·4 (sd 6·1) years). Volunteers were assessed at baseline, and at weeks 2 and 4 for anthropometry, BP and pulse wave velocity. Cortisol and cortisone levels in urine and saliva were determined by specific ELISA methods, and the cortisol/cortisone ratio was calculated. Fasting blood samples were obtained to assess plasma lipids, glucose, insulin and insulin resistance (homeostasis model assessment of insulin resistance). Volunteers consumed 500 ml of PJ or 500 ml of a placebo drink containing a similar amount of energy. Cortisol urinary output was reduced but not significant. However, cortisol/cortisone ratios in urine (P = 0·009) and saliva (P = 0·024) were significantly decreased. Systolic BP decreased from 136·4 (sd 6·3) to 128·9 (sd 5·1) mmHg (P = 0·034), and diastolic BP from 80·3 (sd 4·29) to 75·5 (sd 5·17) mmHg (P = 0·031) after 4 weeks of fruit juice consumption. Pulse wave velocity decreased from 7·5 (sd 0·86) to 7·44 (sd 0·94) m/s (P = 0·035). There was also a significant reduction in fasting plasma insulin from 9·36 (sd 5·8) to 7·53 (sd 4·12) mIU/l (P = 0·025) and of homeostasis model assessment of insulin resistance (from 2·216 (sd 1·43) to 1·82 (sd 1·12), P = 0·028). No significant changes were seen in the placebo arm of the study. These results suggest that PJ consumption can alleviate key cardiovascular risk factors in overweight and obese subjects that might be due to a reduction in both systolic and diastolic BP, possibly through the inhibition of 11β-hydroxysteroid dehydrogenase type 1 enzyme activity as evidenced by the reduction in the cortisol/cortisone ratio. The reduction in insulin resistance might have therapeutic benefits for patients with non-insulin-dependent diabetes, obesity and the metabolic syndrome.

Biomechanics and Blood Pressure with Modeling of Pulse Wave Velocity Based on Multiple Linear Regression

2014 ◽  
Vol 952 ◽  
pp. 261-264
Author(s):  
Long Jia
Keyword(s):  
Blood Pressure ◽  
Linear Regression ◽  
Pulse Wave Velocity ◽  
Regression Model ◽  
Multiple Linear Regression ◽  
Wave Velocity ◽  
Pulse Wave ◽  
Model Assessment ◽  
Practical Test ◽  
Significant Difference

The purpose of present study is to build a multiple linear regression model using biomechanical theory to assess the relationship of pulse wave velocity (PWV) with blood pressure, height and age. By testing the PWV, blood pressure, height, weight of 164 female adults aged above 45 and existing data, the author constructed a multiple linear regression equation. Through comparing the practical test PWV values with the estimate values from regression model, the result showed that there was no significant difference between the model assessment and practical test values (t=0.833, p=.423>.05). Therefore, the regression model is fit for assessing PWV value by height, age, systolic and diastolic pressure.

scholarly journals Effectiveness of in insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other ARBs

2019 ◽  
pp. 70-79 ◽  
Author(s):  
S. V. Nedogoda ◽  
E. V. Chumachek ◽  
V. V. Tsoma ◽  
A. S. Salasyuk ◽  
V. O. Smirnova ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Pulse Wave Velocity ◽  
Wave Velocity ◽  
Pulse Wave ◽  
Augmentation Index ◽  
Model Assessment ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Previous Therapy ◽  
Azilsartan Medoxomil

Aim. To assess the possibility of azilsartan medoxomil to achieve target blood pressure (BP) (less than 130/80 mm Hg), to study angioprotective features and reduction of adipokines levels and inflammatory markers in patients with hypertension and previous therapy with other ARBs.Material and methods. In open observational study with 24 weeks follow-up were included 60 patients with previous therapy (losartan or valsartan or telmisartan).All patients underwent ambulatory BP monitoring, applanation tonometry (determination of the augmentation index and central BP), measurement of the pulse wave velocity, laboratory tests (lipid profile, uric acid, fasting glucose, Homeostasis Model Assessment, homocysteine, leptin, adiponectin, highly sensitive C-reactive protein, tumor necrosis factor alpha, interleukin-6).Results. Azilsartan provided the systolic BP (29,05%, 22,5% and 8,9%) and diastolic BP reduction 18,82%, 20,46% and 8,54% (p<0,05) in patients previously treated with losartan, valsartan or telmisartan, respectively. Central systolic BP (by 25,95%, 8,78%, 11,94%), central pulse BP (by 40%, 18,38% and 19,6%), augmentation index (by 28,87%, 20,69% and 14,29%) and pulse wave velocity (by 21,57%, 24,56% and 24,92%) were decreased (p<0,05). There were positive changes in leptin, C-reactive protein, IL-6, adiponectin levels in all patients with losartan, valsartan or telmisartan initial therapy (p<0,05).Conclusion. Azilsartan medoxomil has advantages in BP control, the arterial elasticity improving, reducing of insulin-resistance and inflammation.

scholarly journals OPTIMAL ORGANOPROTECTION, CONTROL OF bLOOD PRESSURE AND METAbOLIC DISORDER  WITH THE FIxED COMbINATION OF LISINOPRIL, AMLODIPINE AND ROSUVASTATIN IN SYSTEMIC  HYPERTENSION

2018 ◽  
pp. 49-55
Author(s):  
S. V. Nedogoda ◽  
E. V. Chumachek ◽  
A. A. Ledyaeva ◽  
V. V. Tsoma ◽  
A. S. Salasyuk ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Blood Pressure ◽  
Pulse Wave Velocity ◽  
Wave Velocity ◽  
Antihypertensive Therapy ◽  
Pulse Wave ◽  
Fixed Combination ◽  
Augmentation Index ◽  
Resistance Index ◽  
Systemic Hypertension

Aim. Evaluation of the ability of the fixed combination of lisinopril, amlodipine and rosuvastatin (Equamer) in achievement of additional angioprotection in patients with systemic arterial hypertension (AH) and high pulse wave velocity (PWV), regardless of previous antihypertensive therapy (AHT).Material and methods. To the open multicenter observational study 24 weeks duration, 60 patients included, taking double AHT during 6 months. All participants underwent ambulatory 24 hour blood pressure (BP) monitoring, applanation tonometry (augmentation index and central BP), pulse wave velocity assessment, laboratory tests (lipids, fasting glucose, insulin resistance index (HOMA), leptin, high sensitive C-reactive protein (hsCRP) before and after transition to the fixed combination of lisinopril, amlodipine and rosuvastatin (Equamer).Results. By the data from office BP measurement, after transition of patients from the double combinations to fixed combination of lisinopril, amlodipine and rosuvastatin, there was additional decrease of systolic BP (SBP) by 14,3% and diastolic BP (DBP) by 18,5%. By the data from ABPM, decrease of SBP was 16,1%, and DBP — 21,8%. Combination of lisinopril, amlodipine and rosuvastatin decreased PWV by 14,4%, augmentation index by 14,5%, central SBP by 8,1% (p<0,01 for all comparisons with baseline). Fixed combination of lisinopril, amlodipine and rosuvastatin made it to decrease low density lipoproteides by 44%, triglycerides by 36,1% and increase of high density lipoproteides by 10,3% (p<0,01 for all with baseline). Usage of combination of lisinopril, amlodipine and rosuvastatin showed significant decrease of insulin resistance, hsCRP and leptin levels.Conclusion. Fixed combination of lisinopril, amlodipine and rosuvastatin makes it to better control BP, improve vascular elasticity parameters (augmentation index, PWV, central BP) and facilitates the improvement of lipid and glucose metabolism, decrease of inflammation, leptin resistance in patients taking at baseline double antihypertensive therapy.

scholarly journals Association of Insulin Resistance with Vascular Ageing in a General Caucasian Population: An EVA Study

2021 ◽  
Vol 10 (24) ◽  
pp. 5748
Author(s):  
Leticia Gómez-Sánchez ◽  
Marta Gómez-Sánchez ◽  
Cristina Lugones-Sánchez ◽  
Olaya Tamayo-Morales ◽  
Susana González-Sánchez ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Cardiovascular Disease ◽  
Regression Analysis ◽  
Pulse Wave Velocity ◽  
Wave Velocity ◽  
Pulse Wave ◽  
Positive Association ◽  
Caucasian Population ◽  
Model Assessment ◽  
Vascular Ageing

The data on the relationship between insulin resistance and vascular ageing are limited. The aim of this study was to explore the association of different indices of insulin resistance with vascular ageing in an adult Caucasian population without cardiovascular disease. We selected 501 individuals without cardiovascular disease (mean age: 55.9 years, 50.3% women) through random sampling stratified by sex and age. Arterial stiffness was evaluated by measuring the carotid-to-femoral pulse wave velocity (cfPWV) and brachial-to-ankle pulse wave velocity (baPWV). The participants were classified into three groups according to the degree of vascular ageing: early vascular ageing (EVA), normal vascular ageing (NVA) and healthy vascular ageing (HVA). Insulin resistance was evaluated with the homeostatic model assessment of insulin resistance (HOMA-IR) and another five indices. The prevalence of HVA and EVA was 8.4% and 21.4%, respectively, when using cfPWV, and 7.4% and 19.2%, respectively, when using baPWV. The deterioration of vascular ageing, with both measurements, presented as an increase in all the analysed indices of insulin resistance. In the multiple regression analysis and logistic regression analysis, the indices of insulin resistance showed a positive association with cfPWV and baPWV and with EVA.

scholarly journals Insulin resistance and arterial stiffness: impact of gestational diabetes on pulse wave velocity

2018 ◽  
Vol 6 (9) ◽  
pp. 2895
Author(s):  
Aissatou Seck ◽  
Fatou Diallo Agne ◽  
Abibatou Sall Fall ◽  
Fatou Binetou Sar ◽  
Valentin Ouedraogo ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Blood Pressure ◽  
Arterial Stiffness ◽  
Gestational Diabetes ◽  
Pulse Wave Velocity ◽  
Total Cholesterol ◽  
Wave Velocity ◽  
Ldl Cholesterol ◽  
Pulse Wave ◽  
History Of

Background: Gestational diabetes is an intolerance of glucose with the first appearance during the pregnancy. This hyperglycaemia status, because of the pre-existing insulin-resistance, constitute a favourable land of arterial stiffness. The aim of this study is to determine the impact of non obese gestational diabetes on arterial stiffness by measuring the pulse wave velocity (PWV).Methods: We recruited 60 pregnant women aged from 20 to 35 years old. They were between twentieth four and thirtieth five weeks of gestational age. Subjects were divided into two groups: the first group (G1), considered as control group, included 25 normoglycemic pregnant subjects without any history of illness or risk factors of gestational diabetes; the second group (G2) included 35 women with Gestational Diabetes Mellitus (GDM). All pregnant women had not history of smoking, were not taking decoction or medicine, which could disturb pregnancy evolution. Anthropo-physiological and biochemical parameters studied, were: age, body mass index (BMI), blood pressure (BP), triglyceride, cholesterol and HOMA-IR index. The PWV between finger and toe (PWVft) was measured by pOpmètre®.Results: The two groups are matched by age (G1:28±4ans; G2:29±3ans) and BMI (G1:25.6±1.27; G2:26.9±1.3). Blood pressure (BP) values are in normal interval (systolic BP: [110-132mmHg]; diastolic BP: [63-87mmHg]; mean BP: [79-103mmHg]). Total cholesterol (G1:0.95±0.08;G2:2.4±0.7; p˂0.0001), HDL cholesterol (G1:0.44±0.02; G2:0.76±0.2; p˂0.0001, LDL cholesterol (G1:0.40±0.05; G2:1.3±0.5; p˂0.0001), triglyceride (G1:0.57±0.45; G2:1.6±0.4;p˂0.0001), HOMA.IR (G1:1.31±1.05; G2:7.4±1.07; p˂0.01), PWVft (G1:5.99±1.23; G2:10.3±1.9; p˂0.0001) are significantly higher in diabetic group. PWVft is positively correlate to HOMA-IR index, total cholesterol, LDL cholesterol and triglycerides (r=0.3348, p=0.032; r=0.5275, p˂0.0001; r=0.4855,p˂0.0001; r=0.5581, p˂0.0001respectively).Conclusions: Gestational diabetes might induce an increase of pulse wave velocity expressing increment of arterial stiffness. This last constitute an early underlying cardiovascular risk. 

Abstract P142: Association of the Metabolic Syndrome With Pulse Wave Velocity: The Atherosclerosis Risk in Communities Study (ARIC)

Circulation ◽  
2015 ◽  
Vol 131 (suppl_1) ◽  
Author(s):  
Anna K Poon ◽  
Michelle L Snyder ◽  
Elizabeth Selvin ◽  
James S Pankow ◽  
David Couper ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Arterial Stiffness ◽  
Pulse Wave Velocity ◽  
Wave Velocity ◽  
Abdominal Obesity ◽  
Pulse Wave ◽  
Fasting Glucose ◽  
Metabolic Abnormalities ◽  
The Metabolic Syndrome

Introduction: Arterial stiffness is an indicator of subclinical cardiovascular disease (CVD) and is associated with increased CVD risk. The determinants of arterial stiffness may be explained in part by a clustering of metabolic abnormalities (as defined by the metabolic syndrome). Our goal was to examine the association of central and peripheral arterial stiffness (as measured by carotid-femoral, brachial-ankle, and femoral-ankle pulse wave velocity) with the metabolic syndrome in older adults. We predicted higher arterial stiffness (i.e. higher pulse wave velocity measurements) in persons with compared to persons without the metabolic syndrome. Methods: We analyzed 3542 persons without diabetes at the ARIC Visit 5 examination in 2011-13 (61% female; 18% African American; median age 75 yrs). The metabolic syndrome was defined as ≥3 of the following: (1) abdominal obesity (waist circumference ≥102 cm in males and ≥88 cm in females); (2) hypertriglyceridemia (≥150 mg/dL), (3) low HDL-cholesterol (<40 mg/dL in males and <50 mg/dL in females), (4) high blood pressure (BP) (systolic BP ≥130 mmHg and/or diastolic BP≥85 mmHg and/or BP-lowering medications), and (5) high fasting glucose (≥100 mg/dL). Pulse wave velocity (PWV) included carotid-femoral PWV (cfPWV), brachial-ankle PWV (baPWV), and femoral-ankle PWV (faPWV); values were measured using the Colin VP-1000 Plus system (Omron Co., Ltd., Kyoto, Japan). Multivariable regression, with adjustment for age, sex, and race-center, was used to evaluate the association of cfPWV, baPWV, and faPWV with the metabolic syndrome, with each component metabolic abnormality, and with the number of metabolic abnormalities. Results: The prevalence of metabolic syndrome was 49% (SE 2); the three metabolic abnormalities with the highest prevalence were abdominal obesity (63% (SE 1)), elevated fasting glucose (60% (SE 1)), and high blood pressure (76% (SE 1)). A majority of participants had two (29% (SE 3)) or three (28% (SE 3)) metabolic abnormalities. Persons with the metabolic syndrome had a higher mean cfPWV (54 cm/s; 95% CI: 35, 73 cm/s), higher mean baPWV (22; 95% CI: 2, 42 cm/s, respectively), and lower mean faPWV (-18 cm/s; 95% CI: -31, -6 cm/s) compared to persons without the metabolic syndrome. Each additional metabolic abnormality was associated with a 28 cm/s (95% CI: 20, 36 cm/s) higher cfPWV, 19 cm/s (95% CI: 11, 27 cm/s) higher baPWV, and 6 cm/s (95% CI: -11, -1 cm/s) lower faPWV. Conclusion: Metabolic syndrome and each additional metabolic abnormality was positively associated with cfPWV and baPWV, and inversely associated with faPWV in older adults. Abdominal obesity, elevated fasting glucose, and high blood pressure were the most common metabolic abnormalities in this cohort of older men and women. Having the metabolic syndrome and its abnormalities may contribute to arterial stiffness that is predictive of CVD events and mortality.

THE ELASTICITY OF THE LARGE ARTERIES IN HYPERTENSION

1952 ◽  
Vol 30 (2) ◽  
pp. 125-129
Author(s):  
J. P. Adamson ◽  
J. Doupe
Keyword(s):  
Blood Pressure ◽  
Pulse Wave Velocity ◽  
Wave Velocity ◽  
Pulse Wave ◽  
Diastolic Pressure ◽  
Arterial Elasticity ◽  
Large Arteries ◽  
Wave Velocities

Intra-arterial pressures and pulse wave velocities were measured in 18 subjects whose auscultatory diastolic pressures ranged from 45 to 120 mm. Hg. Various methods were used to lower the blood pressure in the hypertensive and to raise it in nonhypertensive subjects so that pulse wave velocities might be compared in all subjects at a common diastolic pressure. The pulse wave velocities were calculated for a diastolic pressure of 80 mm. Hg. No significant differences were found between hypertensive and nonhypertensive subjects. It was concluded that a defect of arterial elasticity as gauged by pulse wave velocity is not a factor in the pathogenesis of hypertension.

scholarly journals Normal and reference values for cardiovascular magnetic resonance-based pulse wave velocity in the middle-aged general population

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Max J. van Hout ◽  
Ilona A. Dekkers ◽  
Jos J. Westenberg ◽  
Martin J. Schalij ◽  
Ralph L. Widya ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Magnetic Resonance ◽  
Magnetic Resonance ◽  
General Population ◽  
Pulse Wave Velocity ◽  
Wave Velocity ◽  
Reference Values ◽  
Pulse Wave ◽  
Disease Risk ◽  
Cardiovascular Disease Risk

Abstract Background Aortic stiffness, assessed through pulse wave velocity (PWV), is an independent predictor for cardiovascular disease risk. However, the scarce availability of normal and reference values for cardiovascular magnetic resonance imaging (CMR) based PWV is limiting clinical implementation. The aim of this study was to determine normal and reference values for CMR assessed PWV in the general population. Methods From the 2,484 participants of the Netherlands Epidemiology of Obesity (NEO) study that have available CMR-PWV data, 1,394 participants free from cardiovasculard disease, smokers or treatment for diabetes, hypertension or dyslipidaemia were selected (45–65 years, 51% female). Participants were divided into sex, age and blood pressure (BP) subgroups. Normal values were specified for participants with a BP < 130/80 mmHg and reference values for elevated BP subgroups (≥ 130/80 and < 140/90 mmHg; and ≥ 140/90 mmHg). Differences between groups were tested with independent samples t-test or ANOVA. Due to an oversampling of obese individuals in this study, PWV values are based on a weighted analysis making them representative of the general population. Results Normal mean PWV was 6.0 m/s [95% CI 5.8–6.1]. PWV increased with advancing age and BP categories (both p < 0.001). There was no difference between sex in normal PWV, however in the BP > 140/90 mmHg women had a higher PWV (p = 0.005). The interpercentile ranges were smaller for participants < 55 years old compared to participants ≥ 55 years, indicating an increasing variability of PWV with age. PWV upper limits were particularly elevated in participants ≥ 55 years old in the high blood pressure subgroups. Conclusion This study provides normal and reference values for CMR-assessed PWV per sex, age and blood pressure category in the general population.

Sign in / Sign up

Export Citation Format

Share Document